Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Rilematovir with Itraconazole and Rifampicin
NCT02729467Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2016
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rilematovir in respiratory syncytial virus infection (RSV) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Analyte Concentration up to 11 days, Area Under the Analyte Concentration-Time Curve From Time 0 to Last Measurable Concentration up to 11 days and 2 more. Started Mar 2016; status: completed.
02
Drugs
rilematovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02729467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02729467.